| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.3 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.3 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |